RevealDx recently appointed Contextflow as its exclusive distributor in the European Union (EU) and selected territories, with the companies also offering trial installation discounts for select customers.
The companies will launch their integrated software at the upcoming International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Vienna in August.
RevealDx has developed RevealAI-Lung, a computer-aided detection (CADx) software application that characterizes lung nodules. The company recently completed a clinical trial and is highlighting how the software provided "significant improvement" in both early detection of malignant nodules and reduction in false positive nodules in the study.
Contextflow, meanwhile, develops artificial intelligence (AI)-based medical devices for radiologists evaluating chest CT images. One such technology is Search Lung CT, a clinical decision support system that detects, quantifies, and visualizes key disease patterns and lung nodules in CT lung images.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
